China Medical GatewayLoading your healthcare gateway…

Li Kai

Li Kai — Chief Physician — Medical Oncology — Tianjin Medical University Cancer Hospital

Specialties

Specializes in chemotherapy and precise targeted therapy for various drug-resistant and difficult-to-treat lung cancers.

Education

Graduated from Tianjin Medical University in 1984, and in the same year started working at the Tianjin Medical University Cancer Hospital.

Professional Experience

Male, Chief Physician, Professor, Director of the Department of Pulmonary Oncology at Tianjin Medical University Cancer Institute and Hospital, Deputy Director of the Tianjin Lung Cancer Diagnosis and Treatment Center, Deputy Director of the Clinical Pharmacology Test Base for Anti-Cancer New Drugs at Tianjin Medical University Cancer Institute and Hospital, Master's Supervisor. He graduated from Tianjin Medical University in 1984 and started working at Tianjin Medical University Cancer Institute and Hospital the same year. He was promoted to attending physician in 1992, and was exceptionally promoted to deputy chief physician and chief physician in 1996 and 2000, respectively. He currently serves as the Director of the Department of Oncology at Tianjin Medical University Cancer Institute and Hospital and Deputy Director of the Clinical Pharmacology Test Base for Anti-Cancer New Drugs at the same hospital. In 1997, he was appointed a member of the Tianjin Pharmaceutical Experts Association. He studied clinical oncology treatment in 1989 and 1998 at Nord Hospital, affiliated with the Medical School in Nantes, France, and at the Cancer Hospital of the Chinese Academy of Medical Sciences. In 2001, he undertook postdoctoral research in drug-resistant tumor molecular biology experimental diagnostics and clinical treatment at the University of California, USA. Over the years, he has been engaged in the research and treatment of various tumors (such as lung cancer, lymphoma, breast cancer, etc.) with chemotherapy and targeted therapies, especially for some drug-resistant and refractory tumors. He has given numerous specialized lectures at home and abroad and has repeatedly led national clinical trials for new anti-cancer drugs, being a leading figure in the field of medical oncology. He specializes in the treatment of various drug-resistant and stubborn tumors. The project he led, "Anti-angiogenesis Combined with Chemotherapy for the Treatment of Non-Small Cell Lung Cancer," increased the clinical benefit rate of advanced non-small cell lung cancer by nearly 20% and extended survival time by nearly 4 months. The research results have attracted the attention of international peers. In 2005, he was invited to speak and received an award at the 18th Asia-Pacific Oncology Conference, and in 2007, he was invited to speak at the world's largest M.D. Anderson Cancer Center in the United States, becoming the first medical oncologist in Tianjin to receive this honor.

Professional Roles

Deputy Director of the Targeted Therapy Committee of the Chinese Anti-Cancer Association Executive Member of the Precision Medicine Committee Member of the Chemotherapy Committee and Lung Cancer Committee Deputy Director of the Tianjin Lung Cancer Diagnosis and Treatment Center Member of the Executive Committee of the Chinese Society of Clinical Oncology (CSCO) Chairman of the Vascular Targeted Therapy Committee Member of the Antitumor Drug Safety Management Committee Executive Member of the Tumor Targeted Therapy Branch of the Chinese Society of Biomedical Engineering Deputy Director of the Oncology Committee of the Chinese Research Hospital Association Active Member of the American Association for Cancer Research (AACR) Editorial board member of Chinese Journal of Oncology, Chinese Journal of Lung Cancer, and Journal of Clinical Oncology

Return to Home